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Metabolite Depletion
Affects Flux Profiling of
Cell Lines
A. Nilsson,1 J.R. Haanstra,2
B. Teusink,2 and J. Nielsen1,3,*
Quantifying the rate of consump-
tion and release of metabolites (i.
e., flux profiling) has become inte-
gral to the study of cancer. The
fluxes as well as the growth of the
cellsmay be affected bymetabolite
depletion during cultivation.
Reprograming of metabolism is an
emerging hallmark of cancer [1]. This fore-
bodes deep insights to be gained from
quantifying the metabolic fluxes of tumors
and cell lines. For microbial organisms,
intracellular fluxes are routinely estimated
by integrating changes in extracellular
metabolite concentrations with genome-
scale metabolic models, but there are
only a few studies of cancer metabolism
taking this approach [2].
In an impressive study of the 60 cancer cell
lines in the National Cancer Institute (NCI)
panel [3], specific exchange fluxes (on a
per-cell, per-time unit basis, i.e., in mmol/
cell/h) were estimated for 115metabolites.
This study is highly citedand thesedataare
extensively usedby others [4–7], for exam-
ple, to calculate the metabolic flux states
for each cell line by mathematical model-
ing. The study measured metabolite con-
centrations in the cultivation medium after
4–5 days of growth (SSpent) in duplicates,
and the baseline concentrations in ten rep-
licates (SFresh). To calculate specific
exchange fluxes from concentration differ-
ences, the amount of cells at each time
pointmustbeknown,giving theareaunder
the growth curve. In this study, the area
wasestimatedusing the final cell countand
tabulated doubling times. It has previously
been noted that the fluxes calculated in the
studymaynotbecomparablebetweencell
types due to the order of magnitude differ-
ences in cell volume [6]. Here we discuss
how metabolite depletion during the cell
cultivationmay affect the estimated fluxes.
The area under the growth curve estimate
relies on the cells being in the exponential
growth phase (Figure 1A). Cell cultures
typically undergo several growth phases:
a lag phase (L), with very low or even
negative growth rates; the first exponen-
tial phase (E1), with rapid growth and high
absorption rates of metabolites; one or
more secondary exponential phases
(E2–EN), with slower growth and meta-
bolic rates; and a stationary phase (S),
with no growth and low metabolic rates
supporting maintenance metabolism.



































































































































Figure 1. Metabolite Depletion May Trigger a Shift from Fast to Slower Exponential Growth, Which Affects the Estimated Flux Profiles. (A) The model
to estimate the area under the growth curve (AModel) using tabulated doubling times will underestimate the true area (AL + AE1 + AE2 + AS) if cells grow beyond the first
exponential phase. This may be triggered by metabolite depletion. (B) Nondepleted cultures (N = 36) show a more glycolytic phenotype, compared with depleted
cultures (N = 84), defined as the final concentration (SSpent) being below 10% of initial concentration (SFresh) for at least one metabolite in the culture. Data from [3]. (C)
The consumption [80_TD$DIFF]rate of serine and release rates of glycine and ornithine aremarkedly higher among the nondepleted cultures, as indicated by normalized flux. P values
calculated using the two-sample Kolmogorov–Smirnov test.
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The switch between E1 and E2 can be
triggered by depletion of a non-essential,
but growth-enhancing metabolite. A
switch to E2 will affect the area under
the growth curve, and is often followed
by shifts in the specific exchange fluxes
and even reabsorption of excreted prod-
ucts (e.g., the co-consumption of glucose
and lactate after glutamate depletion), as
seen in the later stages of CHO cell culti-
vation [8]. The switch to the stationary
phase can be triggered by depletion of
a growth-essential amino acid.
Growth curves were reported for six of the
60 cell lines in the study [3], and several
showed indications of a switch to sec-
ondary exponential phases. As a proxy
for cultures transcending the E1 phase,
we looked for metabolite depletion in the
data. In 70% of the cultures the concen-
tration of at least one metabolite was low
at the endpoint measurement, including
several growth-enhancing or growth-
essential metabolites, for example, gluta-
mine, serine, tryptophan, and valine (see
Supplemental Figure S1 online).
Cultures sampled before metabolite
depletion (nondepleted) showed a more
pronounced glycolytic phenotype
(Figure 1B), characterized by a higher
molar ratio between lactate produced
and glucose consumed compared with
the cultures with depleted metabolites
(depleted). This is consistent with a more
active metabolism in the E1 phase.
Because of differences in cell size and
growth rate, the measured exchange
flux of a metabolite may differ by an order
of magnitude between different cultures
[6]. To adjust for this, we divided each
flux by the median of the flux magnitude
(absolute value) from that culture. These
normalized flux profiles were similar
between the two groups of cell cultures,
but the calculated serine absorption
and release of glycine were markedly
higher for the nondepleted cells
(Figure 1C, Supplemental Figure S2).
This suggests that glycine may have
been reabsorbed to compensate for ser-
ine depletion.
The specific growth rate was lower for the
nondepleted cells (0.020 vs. 0.023 h1 [81_TD$DIFF],
P = 0.02), which may be expected since
fast growing cells are likely to consume
metabolites faster. No difference was,
however, observed in the glycolytic phe-
notype and serine flux between cultures
with specific growth rates below and
above the median (Supplemental
Figure S3).
As metabolite depletion and reabsorption
may affect both the area under the curve
estimate and the metabolic fluxes, cau-
tion is recommended when interpreting
the flux data reported in [3] as specific
fluxes. We provide a list of the nonde-
pleted cultures, which are more likely to
have accurate flux estimates (see Supple-
mental Table S1 online).
To avoid metabolite depletion in meta-
bolic studies of cancer, we recommend
greater medium volumes or shorter cul-
ture times. Ideally, metabolite levels and
cell numbers should be determined at
several time points to get better estima-
tions of specific fluxes and the growth
rate. An example of the added value of
a time-resolved metabolite experiment in
hepatocellular carcinoma cells (Hepg2) is
given in Figure 2. In this experiment, we
monitored cell numbers and medium
metabolites over time, in a similar interval
as the NCI-60 study. The growth curve
showed a shift in growth phase at 50 h,
with continued growth at a lower rate until
80 h. Within this timeframe, glutamine
was depleted. The area under the growth
curve and the exchange fluxes would
have been underestimated if only two
time points were used. Time-resolved
data not only solve this, but may also
reveal important dynamics of the meta-
bolic fluxes.
Supplemental Information
Supplemental information associated with this article
can be found, in the online version, at https://doi.org/
10.1016/j.tibs.2018.03.009.
Figure 2. Metabolic Shifts in a Culture of
Hepg2Cells Undergoing Metabolite Depletion.
Thetime-resolvedcell countsshowashift ingrowth rate
from a first exponential phasewith high growth rate to a
second exponential phase with markedly lower rate.
The switch in growth phase correlates with glutamine
depletion (black dotted line). The expected metabolite
concentrations (blue lines) are calculated by assuming
the indicated specific uptake (mmol/106 cells/h) rates
and are corrected for volume changes due to repeated
sampling (see Supplemental Methods online for details
on the experiment). The specific uptake rates are
refitted to the indicated lowervaluesafter theshift (green
lines), revealing a reduced glycolytic phenotype. Calcu-
lating fluxes using endpoint measurements and the
growth rate from the first exponential phase (red dotted
line) underpredicts theobservedareaunder thecurve; it
would also yield a mixture of the metabolic fluxes from
the two growth phases.
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silencing has been hampered by
delivery issues. A potential solu-
tion is the application of RNA
viruses that generate small RNAs
without any DNA intermediate.
Long-term therapy for various




Many chronic, incurable, and fatal dis-
eases provide no options for efficient
therapy, and long-term consumption of
drugs results in harmful side effects. Cur-
rently, small RNA [89_TD$DIFF] sRNA; small interfering
RNA (siRNA) and/or microRNA (miRNA)]
delivery strategies exploit sRNA-medi-
ated post-transcriptional gene silencing
(pTGS) as a therapeutic approach to treat
various diseases. However, pTGS is
short [90_TD$DIFF]-term and requires continuous
sRNA supply to maintain its effect. This
problem has been addressed by employ-
ing viruses that provide long-term sRNA
expression. However, the drawback of
this approach is that long-term expres-
sion of sRNAs may oversaturate the cel-
lular machinery, affect expression levels
of nontarget genes, and cause toxicity.
Moreover, currently popular viral delivery
vehicles, such as adeno-associated
viruses and lentiviruses, have the capac-
ity to randomly integrate their viral
sequences into the host genome, which
poses a risk of oncogenesis. For addi-
tional information about viral and sRNA
therapy, see Supplemental Information
Box S1 online.
Here, we propose an alternative that
allows a single administration [91_TD$DIFF]of drugs
to safely induce long-term therapeutic
efficacy. Single-stranded self-replicating
RNA viruses can effectively transduce
cells and produce functional sRNAs
[1,2]. These viruses present a great
potential for short-term sRNA delivery
[3] and do not generate any DNA inter-
mediates, thus providing a potentially
safer approach than adeno-associated
viruses and lentiviruses. In addition,
instead of using sRNA-mediated short-
term pTGS, a better solution would be
to use sRNA [92_TD$DIFF]mediated long-term tran-
scriptional gene silencing (TGS). In the
long run, self-replicating RNA viruses
could cause short-term sRNA expression
that would be sufficient to induce long-
term TGS. This approach could lead to
long-term therapeutic effect induced by a
single administration, which could be
especially useful for patients with various
chronic, incurable, and fatal diseases
(Figure 1, Key Figure).
Long-Term TGS
The mechanism for long-term TGS is not
well understood, yet some important
details have already been revealed
(Figure 2). At the active promoter target
site (Figure 2A), sRNA guides the gene
silencing complex with Argonaute 1
(AGO1), DNA methyltransferase 3a
(DNMT3a), and histone deacetylase 1
(HDAC1) serving as core elements
(Figure 2B). It is postulated that sRNAs
guide the gene silencing complex to the
promoter by complementary binding of
promoter-associated RNA, which
remains in close proximity to the promoter
during the transcription (Figure 2C) [4].
Thereafter, this complex increases dime-
thylation at H3K9 [93_TD$DIFF](lysine 9 of histone H3)
and trimethylation at H3K27 (lysine 27 of
histone H3), decreases acetylation at
H3K14 (lysine 14 of histone H3), and indu-
ces TGS (Figure 2D). However, DNA
methylation and a long-term TGS require
maintaining exogenous sRNA levels in the
cell for 7 days [4,5].
The fact that the gene silencing complex
is required to bind to promoter-associ-
ated RNA indicates that TGS could be
applied only for those genes whose pro-
moters are transcribed. It appears that
the promoter transcription is a general
feature in human cells [4], suggesting that
TGS could be universally applied for many
genes.
Epigenetic changes can occur down-
stream from a targeted sRNA locus with-
out changes in upstream sites [5].
Therefore, sRNAs targeting upstream
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